e-learning
resources
London 2016
Sunday, 04.09.2016
Community-acquired pneumonia: from prevention to treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum procalcitonin as a potential biomarker of surgery in parapneumonic pleural effusions
Arturo Cortes-Telles (Merida, Yucatan, Mexico), Arturo Cortes-Telles, Angel Emmanuel Vega-Sanchez, Jose Luis Che-Morales, Danielle Aimee Manjarrez-Martin, Gary Kosai Vargas-Mendoza
Source:
International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Session:
Community-acquired pneumonia: from prevention to treatment
Session type:
Poster Discussion
Number:
603
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Arturo Cortes-Telles (Merida, Yucatan, Mexico), Arturo Cortes-Telles, Angel Emmanuel Vega-Sanchez, Jose Luis Che-Morales, Danielle Aimee Manjarrez-Martin, Gary Kosai Vargas-Mendoza. Serum procalcitonin as a potential biomarker of surgery in parapneumonic pleural effusions. Eur Respir J 2016; 48: Suppl. 60, 603
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Serum albumin and probability of pleural effusion in patients with community-acquired pneumonia
Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections
Year: 2013
Procalcitonin in pleural fluid: A new tool for the diagnosis of empyema and parapneumonic pleural effusions?
Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections
Year: 2011
Protein profiling of pleural fluid in guiding management of infectious parapneumonic effusion in children
Source: International Congress 2015 – Paediatric pulmonary infections
Year: 2015
Pleural fluid procalcitonin levels in identifying pleural effusions due to infection
Source: Annual Congress 2009 - Aetiology and diagnosis of lower respiratory tract infections
Year: 2009
Infectious pleural effusions
Source: ISSN=1025-448x, ISBN=1-904097-25-1, page=204
Year: 2002
Predictive factors, microbiology and outcome of patients with parapneumonic effusion
Source: Eur Respir J 2011; 38: 1173-1179
Year: 2011
Expression of YKL-40 and MIP-1a proteins in exudates and transudates: Biomarkers for differential diagnosis of pleural effusions?
Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies
Year: 2014
Decreasing incidence of parapneumonic pleural effusions (PPE) in children
Source: International Congress 2016 – Paediatric respiratory infections
Year: 2016
Role of markers C-Reactive Protein, Procalcitonin and TREM-1 in diagnosis of infection pleural effusion
Source: International Congress 2018 – Mesothelioma and pleural malignancy: investigations and management
Year: 2018
Empyema and parapneumonic pleural effusion. Prognostic factors about 109 patients
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009
Serum C-reactive protein levels predict the need for surgical intervention in patients with empyema/complicated parapneumonic pleural effusions
Source: International Congress 2019 – Pleural infection and complicated pneumonia
Year: 2019
Pleural fluid C-reactive protein concentration in discriminating uncomplicated from complicated parapneumonic pleural effusion
Source: Annual Congress 2012 - Scores, biomarkers and risk factors in respiratory infections
Year: 2012
Intrapleural tenectaplase therapy in treatment of loculated parapneumonic pleural effusions and empyema
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
Procalcitonin and CRP levels in pleural effusions
Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience
Year: 2009
Pleural fluid IL-6 levels in the identification of the complicated parapneumonic pleural effusion
Source: Annual Congress 2008 - Pleural effusion
Year: 2008
Risk factors associated to surgical treatment of parapneumonic effusion and empyema
Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections
Year: 2013
Human beta defensin-2 serum levels are lower in complicated infectious pleural effusions
Source: Annual Congress 2013 –Interesting research questions
Year: 2013
Role of C-reactive protein in discriminating complicated and uncomplicated parapneumonic effusion from malignant and tuberculous pleural effusion
Source: Virtual Congress 2021 – Clinical problems associated with cough, pleura and respiratory health status
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept